Bloom Energy, Illuminia, Everpure join S&P 500 index. #stocks #be #ilmn #p #sp500 @Bloom_Energy @illumina @EverpureData svdaily.com/2026/09/21/bloom…
1
52
#ILMN
الاغلاق ١٦٢.٣٢$
شهري صاعد✅
طلب اسبوعي صاعد مابين مستويات ١٤٦.٤٥$ الى ١٣٨.٠٦$✅
وقف خساره كسر ١٣٠$ مباشره ❌
القيمة السوقية للشركة (٢٤.٥٦ مليار دولار)
نشاط الشركة (ادوات علوم الحياه)
3
647
#ILMN Yapay zekaya inanıyorsanız, GPU'lara yatırım yaparsınız. AI ilaç keşfine inanıyorsanız, genomik verisine yatırım yaparsınız. Genomik verinin büyük bölümü Illumina'nın makinelerinden çıkıyor.
Illumina DNA dizileme donanımı ve kimyasalları üretiyor. Alanında tartışmasız lider. Dünya genelinde klinik araştırmaların, hastalık tanı çalışmalarının ve AI biyoteknoloji şirketlerinin neredeyse tamamı Illumina makinelerini kullanıyor. Bu "picks and shovels" mantığı — altın aramaya gidersen kürek sat.
2023-2024 döneminde şirket ciddi sıkıntı yaşadı. GRAIL (kanser erken tespiti şirketi) satın almasını AB ve ABD düzenleyicileri engelledi, zorla sattırdı. Bu süreçte hisse 500 dolardan 100 doların altına indi.
Şimdi ne var? Yeni CEO Al deCipriani Ocak 2026'da göreve başladı. GRAIL baskısından kurtuldu. AI araştırma talebi arttıkça Illumina'nın "NovaSeq X" ailesi dizileme kapasitesi katlanıyor. Şirket içinde de AI süreçlere entegre ediliyor.
Analistlerin çoğunluğu "buy" diyor, ortalama hedef 25.00 dolar. 52 hafta aralığı 11 ile 27.71 dolar. Yani şu an bu aralığın ortasında.
Bu kâğıt için düşünce şu: AI ilaç keşfi büyürse, veri üretim altyapısına talep artar. Illumina bu altyapının en kritik parçası. Platform değerleme değil ama yapısal talep güçlü.
Deftere almadım ama not tutuyorum.
2
69
ALT This chart analyses are for educational purposes only. This is not a buy/sell recommendation. Please do your own research before making any trading decisions.
3
132
من منفذ بسهم #ILMN 🚨
يتواصل معي الان📩
nitter.net/messages/compose?recip…
7
28
Speaking at the Amar Ekushey Health Fair in Tower Hamlets on February 21 2025. Unique event blending health and culture on a day that both commemorates and celebrates the importance of linguistic diversity.
#InternationalMotherLanguageDay #ILMN
#EkusheyFebruary #CreativeHealth
1
7
11
702
Illumina, Inc. (#ILMN), founded in 1998 and headquartered in San Diego, California, is a global leader in DNA sequencing and array-based technologies, revolutionizing genomic science. Illumina develops systems that enable the large-scale analysis of genetic variation and function, serving markets in research, clinical diagnostics, and applied genomics. Their product lineup includes sequencing platforms like the NovaSeq series, along with reagents and services for whole-genome sequencing, genotyping, and gene expression analysis. Illumina's technologies are pivotal in areas such as oncology, reproductive health, genetic disease research, and personalized medicine. In Q4 2024, Illumina reported revenues of $1.12 billion, down from the previous year due to competitive pressures and market challenges, with an adjusted EPS of $0.29. The company has been dealing with regulatory scrutiny over its acquisition of GRAIL, a cancer detection company, which it has since decided to divest following EU regulatory orders. Major institutional investors include BlackRock, Vanguard.
1, and FMR LLC. Illumina's strategy
involves innovation in sequencing technology, expanding into new markets like multi-cancer early detection, and navigating patent disputes and competitive landscapes. Challenges include maintaining technological leadership, managing growth in a post-GRAIL acquisition environment, and addressing ethical and privacy concerns in genomics. Despite these, Illumina continues to focus on making genomics more accessible and advancing human health through genetic insights.
1
2
76
Illumina, Inc. (#ILMN), founded in 1998 and headquartered in San Diego, California, is a global leader in DNA sequencing and array-based technologies, revolutionizing genomic science. Illumina develops systems that enable the large-scale analysis of genetic variation and function, serving markets in research, clinical diagnostics, and applied genomics. Their product lineup includes sequencing platforms like the NovaSeq series, along with reagents and services for whole-genome sequencing, genotyping, and gene expression analysis. Illumina's technologies are pivotal in areas such as oncology, reproductive health, genetic disease research, and personalized medicine. In Q4 2024, Illumina reported revenues of $1.12 billion, down from the previous year due to competitive pressures and market challenges, with an adjusted EPS of $0.29. The company has been dealing with regulatory scrutiny over its acquisition of GRAIL, a cancer detection company, which it has since decided to divest following EU regulatory orders. Major institutional investors include BlackRock, Vanguard, and FMR LLC. Illumina's strategy involves innovation in sequencing technology, expanding into new markets like multi-cancer early detection, and navigating patent disputes and competitive landscapes. Challenges include maintaining technological leadership, managing growth in a post-GRAIL acquisition environment, and addressing ethical and privacy concerns in genomics. Despite these, Illumina continues to focus on making genomics more accessible and advancing human health through genetic insights.
4
77
みんなの知らない世界の重要な企業：Illumina #ILMN #株式投資 #バイオインフォマティクス｜takurot @hspeeddigital #note note.com/takurot/n/n91a94b1b…
2
259
🚨 Exciting Update! 📉 My bearish options trade analysis on $ILMN is now live on Substack! Potential 207%+ return! Dive in & share your thoughts! 💼💰 #OptionsTrading #ILMN #BearishTrade #Substack 📉💡
2
453
#ILMN الاغلاق الأسبوعي اسفل مستوى 130.68 والبقاء اسفل مستوى 130.94 الأسبوع القادم يستهدف 122 و الله اعلى واعلم 🌹
2
578
#ILMN الاغلاق الشهري فوق مستوى 139.15 يستهدف 205 سوينج على الشارت الشهري و الله اعلى واعلم 🌹
3
826
